PepGen Inc. (PEPG)
| Bid | 1.43 |
| Market Cap | 48.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -89.98M |
| EPS (ttm) | -2.85 |
| PE Ratio (ttm) | -0.52 |
| Forward PE | -0.65 |
| Analyst | Buy |
| Ask | 1.6 |
| Volume | 158,313 |
| Avg. Volume (20D) | 2,877,045 |
| Open | 1.57 |
| Previous Close | 1.57 |
| Day's Range | 1.48 - 1.64 |
| 52-Week Range | 0.88 - 19.30 |
| Beta | 1.42 |
About PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1...
Analyst Forecast
According to 3 analyst ratings, the average rating for PEPG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 708.08% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
PepGen to Present at the 24th Annual Needham Virtual Healthcare ConferenceBOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
